ClinicalTrials.gg

Program

Psilocybin

Also written as “PEX010-Assisted Therapy”, “COMP360 psilocybin” and “Psilocybin therapy”.

Its studies are mostly in Depressive Disorder, Treatment-Resistant · Stress Disorders, Post-Traumatic · Combat Disorders · Adjustment Disorders · Depressive Disorder, Major, led by 12 companies.

Furthest: phase 3, since Nov 14, 202222 company-led studies, 10 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
COMPASS Pathways83 open or runningphase 3since Nov 14, 2022Dec 11, 2018Nov 2028phase 3 · NCT07570654
MycoMedica Life Sciences PBC30 open or runningphase 1since Mar 5, 2024Mar 5, 2024none ahead
Filament Health22 open or runningphase 2since Sep 19, 2024Sep 19, 2024Dec 2026phase 2 · NCT06608459
Apex Labs11 open or runningphase 2since Nov 8, 2023Nov 8, 2023none ahead
Clairvoyant Therapeutics11 open or runningphase 2since Dec 2, 2022Dec 2, 2022none ahead
Cybin Therapeutics10 open or runningphase 2since Oct 19, 2022Oct 19, 2022none ahead
Eli Lilly10 open or runningphase 1since May 6, 2021May 6, 2021none ahead
Empower Research11 open or runningphase 2since Dec 11, 2023Dec 11, 2023none ahead
Halucenex Life Sciences11 open or runningphase 2since Dec 15, 2021Dec 15, 2021none ahead
Nova Mentis Life Science10 open or runningphase 2since Mar 8, 2023Mar 8, 2023none ahead
optimi-health-corporation10 open or runningearly phase 1since Jan 27, 2022Jan 27, 2022none ahead
Psyence Australia Pty11 open or runningphase 2since Feb 12, 2025Feb 12, 2025Mar 30, 2027phase 2 · NCT07072728

Also a collaborator on its studies: optimapharm, mitacs and KGK Science.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Dec 11, 2018.

  1. Nov 14, 2022Phase 3 study in Depressive Disorder, Treatment-ResistantCOMPASS Pathways · NCT05624268 · 258 enrolled · United States
  2. Dec 2, 2022Clairvoyant Therapeutics's first study: phase 2 study in AlcoholismNew to Clairvoyant TherapeuticsClairvoyant Therapeutics · NCT05646303 · 128 enrolled · Canada, Finland
  3. Jan 25, 2023Phase 3 study in Depressive Disorder, Treatment-ResistantCOMPASS Pathways · NCT05711940 · 572 enrolled · United States, Canada, Czechia and more
  4. Feb 8, 2023Phase 2 study in Depressive Disorder, MajorCOMPASS Pathways · NCT05733546 · 102 enrolled · United States
  5. Mar 8, 2023Nova Mentis Life Science's first study: phase 2 study in Fragile X SyndromeNew to Nova Mentis Life ScienceNova Mentis Life Science · NCT05832255 · 10 enrolled · Canada
  6. Nov 8, 2023Apex Labs's first study: phase 2 study in Stress Disorders, Post-TraumaticNew to Apex LabsApex Labs · NCT06141876 · 160 planned
  7. Dec 11, 2023Empower Research's first study: phase 2 study in PsilocybinNew to Empower ResearchEmpower Research · NCT06471959 · 32 planned · Canada
  8. Mar 5, 2024MycoMedica Life Sciences PBC's first study: phase 1 study in Healthy VolunteersNew to MycoMedica Life Sciences PBCMycoMedica Life Sciences PBC · NCT06326606 · 24 enrolled · Australia
  9. Sep 19, 2024Filament Health's first study: phase 2 study in Opioid-Related DisordersNew to Filament HealthFilament Health · NCT06608459 · 10 planned
  10. Oct 10, 2024Phase 1 study in Healthy VolunteersMycoMedica Life Sciences PBC · NCT06643637 · 16 enrolled · Australia
  11. Oct 29, 2024Phase 2 study in Stimulant Use DisorderFilament Health · NCT06666010 · 86 planned
  12. Feb 12, 2025Psyence Australia Pty's first study: phase 2 study in Adjustment DisordersNew to Psyence Australia PtyPsyence Australia Pty · NCT07072728 · 87 planned · Australia
  13. Jun 16, 2025Phase 1 study in Healthy VolunteerMycoMedica Life Sciences PBC · NCT07050368 · 20 enrolled · United Kingdom
  14. Apr 30, 2026Phase 3 study in Combat DisordersCOMPASS Pathways · NCT07570654 · 300 planned · United States, Canada

Ahead

  1. Dec 2026Primary completion: phase 2 study in Opioid-Related DisordersFilament Health · NCT06608459
  2. Mar 30, 2027Primary completion: phase 2 study in Adjustment DisordersPsyence Australia Pty · NCT07072728
  3. Jan 2028Primary completion: phase 2 study in Stimulant Use DisorderFilament Health · NCT06666010
  4. Nov 2028Primary completion: phase 3 study in Combat DisordersCOMPASS Pathways · NCT07570654

TargetBeta

HTR2A →read by rule
“Serotonin 2a (5-HT2a) receptor agonist”ChEMBL 37, by rule

Other programs on HTR2A

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
paliperidoneruleJohnson & Johnsonphase 4106
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
lurasidoneruleSumitomo Pharmaphase 452
cyclobenzaprineruleTonix Pharmaceuticalsphase 432
iloperidoneruleVanda Pharmaceuticalsphase 415
lumateperoneruleJohnson & Johnsonphase 325
TrazodoneruleAngelini Pharmaphase 314
bretisilocinAbbViephase 21
bretisilocinAbbViephase 11

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07570654Combat Disorders · United States, Canada3RecruitingCOMPASS PathwaysNov 2028300
NCT07050368Healthy Volunteer · United Kingdom1CompletedMycoMedica Life Sciences PBCJan 13, 202620
NCT07072728Adjustment Disorders · Australia2RecruitingPsyence Australia PtyMar 30, 202787
NCT06666010Stimulant Use Disorder2Not yet recruitingFilament HealthJan 202886
NCT06643637Healthy Volunteers · Australia1CompletedMycoMedica Life Sciences PBCMar 12, 202516
NCT06608459Opioid-Related Disorders2Not yet recruitingFilament HealthDec 202610
NCT06326606Healthy Volunteers · Australia1CompletedMycoMedica Life Sciences PBCJul 8, 202424
NCT06471959Psilocybin · Canada2RecruitingEmpower ResearchJul 1, 202532
NCT06141876Stress Disorders, Post-Traumatic2Not yet recruitingApex LabsJun 15, 2025160
NCT05832255Fragile X Syndrome · Canada2SuspendedNova Mentis Life ScienceMay 202410
NCT05733546Depressive Disorder, Major · United States2Active, not recruitingCOMPASS PathwaysSep 2025102
NCT05711940Depressive Disorder, Treatment-Resistant · United States, Canada, Czechia and more3Active, not recruitingCOMPASS PathwaysNov 13, 2025572
NCT05646303Alcoholism · Canada, Finland2Active, not recruitingClairvoyant TherapeuticsAug 31, 2024128
NCT05624268Depressive Disorder, Treatment-Resistant · United States3CompletedCOMPASS PathwaysMay 28, 2025258
NCT05594667Depression · Canada2WithdrawnCybin TherapeuticsMar 14, 20230
NCT05481736Anorexia Nervosa · United States, Ireland, United Kingdom2CompletedCOMPASS PathwaysNov 18, 202432
NCT05312151Stress Disorders, Post-Traumatic · United States, United Kingdom2CompletedCOMPASS PathwaysFeb 12, 202422
NCT05252598ParasomniasEarly 1Withdrawnoptimi-health-corporationAug 20230
NCT05243329Stress Disorders, Post-Traumatic · Canada2Active, not recruitingHalucenex Life SciencesOct 30, 202320
NCT04905121Short Lasting Unilateral Neuralgiform Headache Attacks · United Kingdom1TerminatedEli LillyApr 22, 20224
NCT04739865Depressive Disorder, Treatment-Resistant · United States, Ireland2CompletedCOMPASS PathwaysOct 14, 202119
NCT03775200Depressive Disorder, Treatment-Resistant · United States, Canada, Czechia and more2CompletedCOMPASS PathwaysJul 30, 2021233

How it is read

Names in the registry

  • “Psilocybin”, 16 entries
  • “PEX010-Assisted Therapy”, 2 entries
  • “COMP360 psilocybin”, 1 entry
  • “Psilocybin therapy”, 1 entry
  • “Psilocybin, 1.5 mg”, 1 entry

Codes read as this program: PEX010.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.